Edison Investment Research Limited [GB00BD8GP619 / KEFI]

Respiri (RSH): Initiation — Objective measures for better outcomes

INFORMATION REGLEMENTEE


[23/09/2022 | 22:00]

Edison Investment Research Limited
Respiri (RSH): Initiation — Objective measures for better outcomes

23-Sep-2022 / 21:00 GMT/BST


 

London, UK, 23 September 2022

 

Respiri (RSH): Initiation — Objective measures for better outcomes

Respiri is an Australian medical device and software-as-a-service (SaaS) company, developing a novel remote patient monitoring approach to respiratory health management. Through its integrated wheezo platform (device, application and health portal) the company provides comprehensive (real-time) monitoring for irregular breathing patterns (wheeze), a key physiological variable in asthma and chronic obstructive pulmonary disease. Following its strategic pivot in 2021, Respiri has redirected its focus to the US market, which has a large inadequately treated patient population and a supportive environment for preventative RPM reimbursement. Employing a cost-effective partner-based strategy, management has recently onboarded its first two (US) hospital clients. We initiate coverage with a valuation of A$189.1m or A$0.24/share.

 

We value Respiri at A$189.1m or A$0.24/share based on the epidemiology approach focusing solely on the US market opportunity and assuming a conservative 2% peak target market penetration. With a pro-forma net cash balance of A$2.8m (including A$1.6m equity issue in September 2022), we estimate the need to raise another A$3m before reaching profitability in FY25.


Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Soo Romanoff +44 (0)20 3077 5700 healthcare@edisongroup.com

Jyoti Prakash +44 (0)20 3077 5700 healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        www.linkedin.com/company/edison-group-/

Twitter           www.twitter.com/Edison_Inv_Res

YouTube       www.youtube.com/edisonitv



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1449041  23-Sep-2022 

fncls.ssp?fn=show_t_gif&application_id=1449041&application_name=news&site_id=symex


Read all communications published by Edison Investment Research Limited
Videos
Gestionnaires,
Emetteurs,
My favourite companies
Most read news of Edison Investment Rese...
Dissemination technology Webdisclosure.com - copyright 2022 SYMEX ECONOMICS all rights reserved